{"product_id":"global-measurable-residual-disease-testing-market-growth-status-and-outlook-2023-2029","title":"Global Measurable Residual Disease Testing Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Measurable Residual Disease Testing Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nThe global Measurable Residual Disease Testing market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Measurable Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eMeasurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Measurable Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Measurable Residual Disease Testing sales in 2022, providing a comprehensive analysis by region and market sector of projected Measurable Residual Disease Testing sales for 2023 through 2029. With Measurable Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Measurable Residual Disease Testing industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Measurable Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Measurable Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Measurable Residual Disease Testing market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Measurable Residual Disease Testing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Measurable Residual Disease Testing.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Measurable Residual Disease Testing market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nFlow Cytometry\u003cbr\u003e\nPolymerase Chain Reaction (PCR)\u003cbr\u003e\nNext-Generation Sequencing (NGS)\u003cbr\u003e\nOther\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nHematological Malignancies\u003cbr\u003e\nLeukemia\u003cbr\u003e\nLymphoma\u003cbr\u003e\nSolid Tumors\u003cbr\u003e\nOther\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\n United States\u003cbr\u003e\n Canada\u003cbr\u003e\n Mexico\u003cbr\u003e\n Brazil\u003cbr\u003e\nAPAC\u003cbr\u003e\n China\u003cbr\u003e\n Japan\u003cbr\u003e\n Korea\u003cbr\u003e\n Southeast Asia\u003cbr\u003e\n India\u003cbr\u003e\n Australia\u003cbr\u003e\nEurope\u003cbr\u003e\n Germany\u003cbr\u003e\n France\u003cbr\u003e\n UK\u003cbr\u003e\n Italy\u003cbr\u003e\n Russia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\n Egypt\u003cbr\u003e\n South Africa\u003cbr\u003e\n Israel\u003cbr\u003e\n Turkey\u003cbr\u003e\n GCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nAdaptive Biotechnologies Corporation\u003cbr\u003e\nArcherDX, Inc. (Invitae Corporation)\u003cbr\u003e\nAsuragen\u003cbr\u003e\nArup Laboratories\u003cbr\u003e\nBio-Rad Laboratories\u003cbr\u003e\nCergentis B.V.\u003cbr\u003e\nF. Hoffmann- La Roche Ltd\u003cbr\u003e\nGuardant Health\u003cbr\u003e\nICON plc\u003cbr\u003e\nInvivoscribe\u003cbr\u003e\nLaboratory Corporation of America Holdings\u003cbr\u003e\nMission Bio\u003cbr\u003e\nNatera, Inc.\u003cbr\u003e\nNeoGenomics Laboratories\u003cbr\u003e\nOpko Health\u003cbr\u003e\nQuest Diagnostics Incorporated\u003cbr\u003e\nSysmex Corporation\u003cbr\u003e\nGenetron Health\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 110 Pages \/ MCW16236624","offer_id":47652222992690,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-measurable-residual-disease-testing-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}